CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 1,233,500,000	$ 1,472,700,000	$ 1,890,800,000	$ 1,320,800,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(4,400,000)		(5,100,000)
Net Cash Provided by (Used in) Financing Activities	(17,700,000)		(450,100,000)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	492,100,000		770,100,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation And Amortization Of Leased Assets	48,900,000		48,300,000
Depreciation and amortization	161,500,000		183,900,000
Stock compensation	38,200,000		28,700,000
Asset Impairment Charges	1,200,000		0
Deferred income taxes	(19,000,000.0)		(27,800,000)
Other Operating Activities, Cash Flow Statement	(3,600,000)		(3,200,000)
Change in assets and liabilities (net of effects of acquisitions):
Increase in accounts receivable (net)	(20,400,000)		(146,700,000)
Increase (Decrease) in Unbilled Contract Receivable	84,500,000		42,500,000
Increase in inventories	37,400,000		4,700,000
Decrease in accounts payable	(5,500,000)		(16,900,000)
Increase (Decrease) in Deferred Revenue	(2,900,000)		31,800,000
Increase (Decrease) in Prepaid Expense and Other Assets	41,100,000		51,900,000
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	(212,300,000)		95,100,000
Net cash provided by operating activities	356,000,000.0		1,157,600,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash payments for laboratory-related assets	(117,200,000)		(95,400,000)
Proceeds from sale of assets	1,000,000.0		2,600,000
Proceeds from Sale of Equity Method Investments	400,000		0
Payments to Acquire Equity Method Investments	(2,200,000)		(5,500,000)
Net Cash Provided by (Used in) Investing Activities	(573,100,000)		(132,400,000)
Payments to Acquire Businesses, Net of Cash Acquired	(455,100,000)		(34,100,000)
Net cash used for investing activities	(573,100,000)		(132,400,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Other Long-term Debt	0		375,000,000.0
Payment, Tax Withholding, Share-based Payment Arrangement	27,300,000		28,100,000
Net proceeds from issuance of stock to employees	18,200,000		24,700,000
Payments for Repurchase of Common Stock	0	1,000,000,000	68,500,000
Other Financing Cash Flows	8,600,000		3,200,000
Net cash provided by (used for) financing activities	(17,700,000)		(450,100,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(239,200,000)		$ 570,000,000.0
Cash and cash equivalents at beginning of period	1,472,700,000
Cash and cash equivalents at end of period	$ 1,233,500,000	$ 1,472,700,000